Episode Details

Canopy Growth's Q4 2026 revealed that capturing Canada's top medical market spot came with a brutal, immediate profitability hangover.

In ~10 minutes ⏱️:

• The $10.7M inventory purge triggered by the MTL Cannabis acquisition.

• Why the Storz & Bickel vaporizer division took a $61M impairment.

• How VA reimbursement cuts forced an immediate rewrite of pricing strategies.

• Closing the Kelowna cultivation facility to centralize output and cut costs.

• Management's explicit warning for slower revenue growth in H1 2027.

Despite shedding physical assets and pivoting away from ultra-premium vaporizers, Canopy exited the quarter with a strong $131 million net cash position. The post-earnings market reaction was entirely flat as investors weigh the short-term pain of restructuring against management's promise of adjusted EBITDA profitability next year.

Canopy Growth Corporation (CGC) | Q4 FY2026

AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.